Dashboard
Manage Tickers

MRK Merck & Co., Inc.

NYSE merck.com


$ 86.10 $ -0.30 (-0.35 %)    

Friday, 31-Oct-2025 18:55:30 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 629.16 $ 3.02 (0.48 %)
DIA $ 475.58 $ 0.66 (0.14 %)
SPY $ 681.80 $ 2.23 (0.33 %)
TLT $ 90.21 $ -0.27 (-0.3 %)
GLD $ 368.20 $ -2.01 (-0.54 %)
$ 85.98
$ 85.22
$ 86.06 x 25
$ 86.11 x 20
$ 84.56 - $ 86.46
$ 71.87 - $ 101.32
12,384,986
na
214.76B
$ 0.26
$ 13.09
TBD
na
na ($ 0.04)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-05-2025 06-30-2025 10-Q
2 05-02-2025 03-31-2025 10-Q
3 02-25-2025 12-31-2024 10-K
4 11-06-2024 09-30-2024 10-Q
5 08-05-2024 06-30-2024 10-Q
6 05-03-2024 03-31-2024 10-Q
7 02-26-2024 12-31-2023 10-K
8 11-03-2023 09-30-2023 10-Q
9 08-07-2023 06-30-2023 10-Q
10 05-05-2023 03-31-2023 10-Q
11 02-24-2023 12-31-2022 10-K
12 11-03-2022 09-30-2022 10-Q
13 08-04-2022 06-30-2022 10-Q
14 05-05-2022 03-31-2022 10-Q
15 02-25-2022 12-31-2021 10-K
16 11-05-2021 09-30-2021 10-Q
17 08-09-2021 06-30-2021 10-Q
18 05-05-2021 03-31-2021 10-Q
19 02-25-2021 12-31-2020 10-K
20 11-05-2020 09-30-2020 10-Q
21 08-05-2020 06-30-2020 10-Q
22 05-06-2020 03-31-2020 10-Q
23 02-26-2020 12-31-2019 10-K
24 11-05-2019 09-30-2019 10-Q
25 08-06-2019 06-30-2019 10-Q
26 05-08-2019 03-31-2019 10-Q
27 02-27-2019 12-31-2018 10-K
28 11-06-2018 09-30-2018 10-Q
29 08-07-2018 06-30-2018 10-Q
30 05-08-2018 03-31-2018 10-Q
31 02-27-2018 12-31-2017 10-K
32 11-07-2017 09-30-2017 10-Q
33 08-08-2017 06-30-2017 10-Q
34 05-09-2017 03-31-2017 10-Q
35 02-28-2017 12-31-2016 10-K
36 11-07-2016 09-30-2016 10-Q
37 08-08-2016 06-30-2016 10-Q
38 05-09-2016 03-31-2016 10-Q
39 02-26-2016 12-31-2015 10-K
40 11-05-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles
Governor Of Virginia Says Industry Partner...
10/31/2025 21:01:26

-Reuters

eli-lilly-extends-lead-in-150b-obesity-drug-race-as-novo-pfizer-clash--heres-how-etfs-stand-to-gain
Eli Lilly Extends Lead In $150B Obesity Dr...
10/30/2025 20:04:44

As Eli Lilly, Novo Nordisk, and Pfizer battle for dominance in the obesity-drug market, these ETFs are offering exposure to the...

meta-tumbles-10-google-marks-historic-rally-whats-moving-markets-thursday
Meta Tumbles 10%, Google Marks Historic Ra...
10/30/2025 17:40:46

Wall Street saw a cautious tone on Thursday as major tech-heavy indexes edged lower, weighed down by mixed earnings from the me...

merck-ready-for-larger-than-15-billion-deals-raises-annual-profit-outlook
Merck Ready For Larger Than $15 Billion De...
10/30/2025 16:24:17

Merck shares dipped after strong earnings and higher profit guidance, as the company narrowed its 2025 sales forecast amid mixe...

merck-exec-says-co-continues-to-be-focused-in-a-1b-to-15b-range-for-potential-deal-size-and-is-willing-to-go-larger
Merck Exec Says Co Continues To Be Focused...
10/30/2025 13:42:05

- Reuters Citing Conf Call

earnings-scheduled-for-october-30-2025
Earnings Scheduled For October 30, 2025
10/30/2025 11:12:06

wall-streets-most-accurate-analysts-give-their-take-on-3-health-care-stocks-delivering-high-dividend-yields
Wall Street's Most Accurate Analysts Give ...
10/30/2025 11:09:08

merck-raises-fy2025-adj-eps-guidance-from-887-897-to-893-898-vs-891-est-narrows-fy2025-sales-guidance-from-64300b-65300b-to-64500b-65000b-vs-64662b-est
Merck Raises FY2025 Adj EPS Guidance from ...
10/30/2025 10:32:08

Full-Year 2025 Financial Outlook The following table summarizes the Company's full-year financial outlook. Full Year 2025  ...

merck--co-q3-2025-adj-eps-258-beats-235-estimate-sales-17276b-beat-16963b-estimate
Merck & Co Q3 2025 Adj. EPS $2.58 Beats $2...
10/30/2025 10:30:55

merck-and-eisai-partnered-phase-3-leap-012-trial-of-keytruda-pembrolizumab-plus-lenvima-lenvatinib-in-combination-with-transarterial-chemoembolization-for-hepatocellular-carcinoma-liver-cancer-did-not-achieve-statistical-significance-for-overall-survival
Merck And Eisai Partnered Phase 3 LEAP-012...
10/29/2025 11:16:38

At a pre-specified interim analysis, KEYTRUDA plus LENVIMA in combination with TACE did not achieve statistical significance fo...

the-european-commission-has-approved-mercks-keytruda-pembrolizumab-as-part-of-the-treatment-regimen-for-resectable-locally-advanced-head-and-neck-squamous-cell-carcinoma
The European Commission Has Approved Merck...
10/29/2025 10:48:06

KEYTRUDA monotherapy now approved as neoadjuvant treatment, continued as adjuvant treatment combined with radiotherapy with or ...

looking-at-merck--cos-recent-unusual-options-activity
Looking At Merck & Co's Recent Unusual Opt...
10/28/2025 18:01:49

mercks-new-cancer-therapy-combo-shows-significant-edge-over-rivals-in-renal-cancer
Merck's New Cancer Therapy Combo Shows Sig...
10/28/2025 17:40:16

Merck and Eisai report Phase 3 results showing Welireg plus Lenvima significantly improved progression-free survival in advance...

mercks-topline-data-from-phase-3-litespark-022-trial-of-keytruda-pembrolizumab-plus-welireg-belzutifan-in-adjuvant-setting-showed-statistically-significant-and-clinically-meaningful-improvement-in-disease-free-survival-for-clear-cell-renal-cell-carcinoma
Merck's Topline Data From Phase 3 LITESPAR...
10/28/2025 10:48:31

First combination regimen to demonstrate improvement in DFS compared to KEYTRUDA monotherapy for these patients in the adjuvant...

merck-and-eisai-partnered-phase-3-litespark-011-trial-of-oral-regimen-of-welireg-belzutifan-plus-lenvima-lenvatinib-met-one-of-its-primary-endpoints-of-progression-free-survival-for-advanced-renal-cell-carcinoma
Merck And Eisai Partnered Phase 3 LITESPAR...
10/28/2025 10:36:53

First treatment regimen to demonstrate a statistically significant improvement in PFS for patients whose disease progressed fol...

how-is-the-market-feeling-about-merck--co-inc
How Is The Market Feeling About Merck & Co...
10/27/2025 16:00:37

fda-expands-approval-of-mercks-winrevair-after-study-shows-76-drop-in-pah-death-and-hospitalization-risk
FDA Expands Approval of Merck's WINREVAIR ...
10/27/2025 10:47:49

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration...

live-on-cnbc-kevin-simpson-announces-bought-more-merck
Live On CNBC, Kevin Simpson Announces Boug...
10/24/2025 16:32:19

merck-to-present-new-research-from-its-cardio-pulmonary-portfolio-pipeline-at-american-heart-association-scientific-sessions-2025-in-new-orleans
Merck To Present New Research From Its Car...
10/23/2025 11:02:29

Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced plans to present new research from the ...

merck-receives-us-fdas-priority-review-for-two-supplemental-biologics-license-applications-for-keytruda-keytruda-qlex-to-treat-muscle-invasive-bladder-cancer-fda-sets-april-7-2026-as-prescription-drug-user-fee-act-date
Merck Receives US FDA's Priority Review Fo...
10/23/2025 10:08:32

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administra...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION